| Recruitment status | Terminated |
| Unique ID issued by UMIN | UMIN000012931 |
| Receipt No. | R000015117 |
| Official scientific title of the study | Effect of azilsartan on 24-h ambulatory blood pressure in patients with CKD and hypertension. |
| Date of disclosure of the study information | 2015/02/01 |
| Last modified on | 2016/07/26 (Ver. 2) |
| Basic information | ||
| Official scientific title of the study | Effect of azilsartan on 24-h ambulatory blood pressure in patients with CKD and hypertension. | |
| Title of the study (Brief title) | Effect of azilsartan on 24-h ambulatory blood pressure in CKD | |
| Region |
|
|
| Condition | ||
| Condition | CKD and hypertension | |
| Classification by specialty |
|
|
| Classification by malignancy | Others | |
| Genomic information | NO | |
| Objectives | |
| Narrative objectives1 | The aim of the study was to measure the effects on blood pressure (BP) of the angiotensin receptor blocker azilsartan medoxomil. |
| Basic objectives2 | Efficacy |
| Basic objectives -Others | |
| Trial characteristics_1 | |
| Trial characteristics_2 | |
| Developmental phase | |
| Assessment | |
| Primary outcomes | The primary endpoint was 24-h systolic BP by ambulatory monitoring. |
| Key secondary outcomes | |
| In outcomes field, the entry of just a few words such as "safety" or "efficiency" will not be accepted. Specify the name of outcome measures, including the time when you plan to measure. Usually, only one primary outcome is accepted. Write the other outcomes in "secondary outcomes" field. |
| Base | |
| Study type | Interventional |
| Study design | |
| Basic design | Single arm |
| Randomization | Non-randomized |
| Randomization unit | |
| Blinding | Open -no one is blinded |
| Control | Uncontrolled |
| Stratification | |
| Dynamic allocation | |
| Institution consideration | |
| Blocking | |
| Concealment | |
| Intervention | ||
| No. of arms | 1 | |
| Purpose of intervention | Treatment | |
| Type of intervention |
|
|
| Interventions/Control_1 | This was a open, cross-over (azilsartan or other ARB) study of 12 weeks' duration in 20 patients with CKD and hypertension. | |
| Interventions/Control_2 | ||
| Interventions/Control_3 | ||
| Interventions/Control_4 | ||
| Interventions/Control_5 | ||
| Interventions/Control_6 | ||
| Interventions/Control_7 | ||
| Interventions/Control_8 | ||
| Interventions/Control_9 | ||
| Interventions/Control_10 | ||
| In interventions field, include the details of interventions, such as duration, amount, and frequency. If the intervention includes prescription or use of medical devices, duration is required. |
| Eligibility | ||||
| Age-lower limit |
|
|||
| Age-upper limit |
|
|||
| Gender | Male and Female | |||
| Key inclusion criteria | Inclusion criteria were following;
-outpatient -a steady dose of ARB other than azilsartan -without hyperkalemia and progression of renal damage by ARB -instructed nutritional guidance -take ARBs for over 3 months -BP of >130/80 mmHg of the run-in period -ABPM was done within 6 months |
|||
| Key exclusion criteria | Exclusion criteria were known hypersensitivity to ARBs, ACE inhibitors or direct renin inhibitors and pregnancy or lactation. | |||
| Target sample size | 20 | |||
| Research contact person | |
| Name of lead principal investigator | Katsuomi Matsui |
| Organization | St. Marianna University School of Medicine |
| Division name | Department of Nephrology and Hypertension, Internal Medicine |
| Address | 2-16-1 Sugao, Miyamae-Ku, Kawasaki 216-8511, Japan |
| TEL | 044-977-8111 |
| m.katsuomi@marianna-u.ac.jp | |
| Public contact | |
| Name of contact person | Katsuomi Matsui |
| Organization | St. Marianna University School of Medicine |
| Division name | Department of Nephrology and Hypertension, Internal Medicine |
| Address | 2-16-1 Sugao, Miyamae-Ku, Kawasaki 216-8511, Japan |
| TEL | 044-977-8111 |
| Homepage URL | |
| m.katsuomi@marianna-u.ac.jp | |
| Sponsor | |
| Institute | Nephrology and Hypertension, St. Marianna University School of Medicine |
| Institute | |
| Department | |
| Sponsor means an organization that is responsible for plan, deployment and report of the research including funding management. It doesn't mean funding agency". Therefore, all clinical trial should have the one. |
| Funding Source | |
| Organization | Nephrology and Hypertension, St. Marianna University School of Medicine |
| Organization | |
| Division | |
| Category of Funding Organization | Self funding |
| Nationality of Funding Organization | |
| Other related organizations | |
| Co-sponsor | |
| Name of secondary funder(s) | |
| Secondary IDs | |
| Secondary IDs | NO |
| Study ID_1 | |
| Org. issuing International ID_1 | |
| Study ID_2 | |
| Org. issuing International ID_2 | |
| IND to MHLW | |
| Institutions | |
| Institutions | |
| Other administrative information | |||||||
| Date of disclosure of the study information |
|
||||||
| Progress | |||||||
| Recruitment status | Terminated | ||||||
| Date of protocol fixation |
|
||||||
| Anticipated trial start date |
|
||||||
| Last follow-up date | |||||||
| Date of closure to data entry | |||||||
| Date trial data considered complete | |||||||
| Date analysis concluded | |||||||
| Related information | |
| URL releasing protocol | |
| Publication of results | Unpublished |
| URL releasing results | |
| Results | |
| Other related information | |
| Management information | |||||||
| Registered date |
|
||||||
| Last modified on |
|
||||||
| Link to view the page | |
| URL(English) | https://upload.umin.ac.jp/cgi-open-bin/icdr_e/ctr_view.cgi?recptno=R000015117 |